ANDHealth – Australia’s national digital health initiative – today announced DoseMe as one of six digital health technologies to be selected for the inaugural ANDHealth+ Program.
“We feel very privileged to be selected for the inaugural ANDHealth+ program and look forward to working with a remarkable set of advisors.
DoseMe was founded with the sole purpose to improve patient care through better dosing, and with ANDHealth’s core focus on achieving outcomes for their cohort, it’s a partnership destined to help deliver precision dosing to the world,” said DoseMe Founder and Chief Scientific Officer, Robert McLeay, PhD.
The ANDHealth program provides support from proven experts across both medtech and pharmaceutical sectors to undertake a significant project focused on securing the clinical or commercial evidence to support a digital technologies market development.
“The ANDHealth process is unique, as unlike many accelerators and grants which focus on very early stage ideas, ANDHealth supports innovative companies like DoseMe, to expand into other marketplaces and sustain that growth.
Developing a strategy for DoseMe in partnership with a talented set of ANDHealth advisors, with expertise ranging from clinical research through to pharmaceutical marketing, is of distinct value as we scale our operations,” said McLeay.